William W L Wong
Overview
Explore the profile of William W L Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saeed Y, Mitsakakis N, Feld J, Krahn M, Kwong J, Wong W
Med Decis Making
. 2025 Feb;
:272989X251319342.
PMID: 39985398
Background: Hepatitis C virus (HCV) infection is associated with reduced quality of life and health utility. It is unclear whether this is primarily due to HCV infection itself or commonly...
2.
Chayab L, Leighl N, Tadrous M, Warren C, Wong W
Curr Oncol
. 2025 Jan;
32(1).
PMID: 39851929
The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited...
3.
Sahakyan Y, Erman A, Wong W, Greenaway C, Janjua N, Kwong J, et al.
Viruses
. 2024 Aug;
16(8).
PMID: 39205198
Background: The World Health Organization (WHO) has set hepatitis C (HCV) elimination targets for 2030. Understanding existing gaps in the "HCV care-cascade" is essential for meeting these targets. We aimed...
4.
Lewis D, Jimenez L, Mansour M, Horton S, Wong W
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001415
Gastric cancer (GC) poses notable economic and health burdens in settings where the incidence of disease is prevalent. Some countries have established early screening and treatment programs to address these...
5.
Greenwald Z, Werb D, Feld J, Austin P, Fridman D, Bayoumi A, et al.
J Clin Epidemiol
. 2024 Mar;
170:111332.
PMID: 38522754
Objectives: Health administrative data can be used to improve the health of people who inject drugs by informing public health surveillance and program planning, monitoring, and evaluation. However, methodological gaps...
6.
Masucci L, Tian F, Tully S, Feng Z, McFarlane T, Chan K, et al.
Med Decis Making
. 2024 Mar;
44(3):296-306.
PMID: 38486447
Background: Chimeric antigen receptor (CAR) T-cell therapy is a novel cell therapy for treating non-Hodgkin lymphoma. The development of CAR T-cell therapy has transformed oncology treatment by offering a potential...
7.
Tian F, Forouzannia F, Feng Z, Biondi M, Mendlowitz A, Feld J, et al.
Hepatology
. 2024 Mar;
80(2):440-450.
PMID: 38478751
Background And Aims: Despite the availability of highly effective direct-acting antiviral therapy, chronic hepatitis C (CHC) continues to cause a major public health burden. In many high-income countries, treatment rates...
8.
Cid A, Mahajan N, Wong W, Beazely M, Grindrod K
Can Pharm J (Ott)
. 2024 Mar;
157(2):84-94.
PMID: 38463179
Aims: To determine the cost-effectiveness of pharmacy-based intranasal (IN) and intramuscular (IM) naloxone distribution in Canada. Methods: We developed a state-transition model for pharmacy-based naloxone distribution, every 3 years, to...
9.
Forouzannia F, Hamadeh A, Passos-Castilho A, Erman A, Yu A, Feng Z, et al.
Liver Int
. 2024 Mar;
44(6):1383-1395.
PMID: 38445848
Background: Patients with chronic hepatitis C (CHC) can be cured with the new highly effective interferon-free combination treatments (DAA) that were approved in 2014. However, CHC is a largely silent...
10.
Erman A, Sahakyan Y, Everett K, Greenaway C, Janjua N, Kwong J, et al.
Can J Gastroenterol Hepatol
. 2024 Mar;
2024:5573068.
PMID: 38434933
Background: Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario,...